AI-generated summary
The authors studied red diode laser light at 650 nm, delivered at fluences from 2 to 10 J/cm2, on two hepatoma cell lines in laboratory culture. They report reduced cell viability, proliferation and hepatitis B subviral particle production, with effects that depended on dose, cell type and time. Because this is a cell study, the findings do not show effects in patients.
- Who or what was studied
- Hepatoma cell lines HepG2.2.15 and HepG2 (laboratory cells, not human participants)
- Wavelengths
- 650 nm
- Limits stated in the abstract
- The study used cultured cell lines rather than patients, and the abstract calls for further research before any clinical application.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Chronic hepatitis B virus (HBV) infection is a serious global health concern, with an increased incidence and risk of developing cirrhosis and hepatocellular carcinoma (HCC). Patients chronically infected with HBV are likely to experience chronic oxidative stress, leading to mitochondrial dysfunction. Photobiomodulation is induced by the absorption of low-level laser therapy (LLLT) with a red or infrared laser by cytochrome C oxidase enzyme, resulting in mitochondrial photoactivation. Although it is widely used in clinical practice, the use of LLL as adjuvant therapy for persistent HBV infection is uncommon. This study aimed to investigate the effect of LLLT dosage from 2 J/cm2 to 10 J/cm2 of red diode laser (650 nm) on both hepatoma cell lines (HepG2.2.15 [integrated HBV genome stable cell model] and non-integrated HepG2), with a subsequent impact on HBVsvp production.
Methods
The present study evaluated the effects of different fluences of low-level laser therapy (LLLT) irradiation on various aspects of hepatoma cell behavior, including morphology, viability, ultrastructure, and its impact on HBVsvp synthesis.
Results
In response to LLLT irradiation, we observed a considerable reduction in viability, proliferation, and HBVsvp production in both hepatoma cell lines HepG2.2.15 and HepG2. Ultrastructural modification of mitochondria and nuclear membranes: This effect was dose, cell type, and time-dependent.
Conclusions
The use of LLLT may be a promising therapy for HCC and HBV patients by reducing cell proliferation, HBVsvp production, and altering mitochondrial and nuclear structure involved in cellular death inducers. Further research is required to explore its clinical application.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nm
- Energy density (fluence)
- 2 J/cm2, 10 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Low-level laser therapy, Cytochrome c oxidase, Photobiomodulation, Oxidative stress, Mitochondria, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.